{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:17:37Z","timestamp":1778635057504,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"am","delay-in-days":414,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.therap.2020.05.010","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T21:34:18Z","timestamp":1590183258000},"page":"363-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence"],"prefix":"10.1016","volume":"75","author":[{"given":"M.","family":"Roustit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Guilhaumou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Molimard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-D.","family":"Drici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-L.","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.therap.2020.05.010_bib0310","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.4049\/jimmunol.165.3.1534","article-title":"Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism","volume":"165","author":"Weber","year":"2000","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.therap.2020.05.010_bib0315","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/annrheumdis-2016-210012","article-title":"Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase","volume":"76","author":"M\u00fcller-Calleja","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.therap.2020.05.010_bib0320","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/jir.2014.0038","article-title":"Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery","volume":"35","author":"Wang","year":"2015","journal-title":"J Interferon Cytokine Res"},{"issue":"6","key":"10.1016\/j.therap.2020.05.010_bib0325","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1073\/pnas.78.6.3605","article-title":"Antihistaminics, local anesthetics, and other amines as antiviral agents","volume":"78","author":"Miller","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.therap.2020.05.010_bib0330","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.therap.2020.05.010_bib0335","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today's diseases","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"21","key":"10.1016\/j.therap.2020.05.010_bib0340","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612043383791","article-title":"Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity","volume":"10","author":"Romanelli","year":"2004","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.therap.2020.05.010_bib0345","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2012.6936","article-title":"Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial","volume":"308","author":"Paton","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.therap.2020.05.010_bib0350","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/vbz.2008.0049","article-title":"On chikungunya acute infection and chloroquine treatment","volume":"8","author":"De Lamballerie","year":"2008","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"5","key":"10.1016\/j.therap.2020.05.010_bib0355","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/v10050268","article-title":"Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection","volume":"10","author":"Roques","year":"2018","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.therap.2020.05.010_bib0360","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1371\/journal.pntd.0000785","article-title":"A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults","volume":"4","author":"Tricou","year":"2010","journal-title":"PLOS Neglected Trop Dis"},{"key":"10.1016\/j.therap.2020.05.010_bib0365","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1743-422X-3-39","article-title":"In vitro inhibition of human influenza A virus replication by chloroquine","volume":"3","author":"Ooi","year":"2006","journal-title":"Virol J"},{"issue":"9","key":"10.1016\/j.therap.2020.05.010_bib0370","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1473-3099(11)70065-2","article-title":"Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial","volume":"11","author":"Paton","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.therap.2020.05.010_bib0375","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00535-009-0132-9","article-title":"Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy","volume":"45","author":"Mizui","year":"2010","journal-title":"J Gastroenterol"},{"issue":"6","key":"10.1016\/j.therap.2020.05.010_bib0380","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1139\/cjpp-2015-0507","article-title":"New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial)","volume":"94","author":"Peymani","year":"2016","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.therap.2020.05.010_bib0385","doi-asserted-by":"crossref","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","volume":"177","author":"Touret","year":"2020","journal-title":"Antivir Res"},{"issue":"1","key":"10.1016\/j.therap.2020.05.010_bib0390","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","article-title":"In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine","volume":"323","author":"Keyaerts","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.therap.2020.05.010_bib0395","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"issue":"8","key":"10.1016\/j.therap.2020.05.010_bib0400","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East Respiratory Syndrome Coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.therap.2020.05.010_bib0405","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.therap.2020.05.010_bib0410","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.therap.2020.05.010_bib0415","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1874","article-title":"Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness","author":"Al-Kofahi","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2020.05.010_bib0420","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.therap.2020.05.010_bib0425","series-title":"Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo","author":"Weston","year":"2020"},{"key":"10.1016\/j.therap.2020.05.010_bib0430","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","author":"Cortegiani","year":"2020","journal-title":"J Crit Care"},{"issue":"1","key":"10.1016\/j.therap.2020.05.010_bib0435","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"BioScience Trends"},{"key":"10.1016\/j.therap.2020.05.010_bib0440","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"105949","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.therap.2020.05.010_bib0445","series-title":"Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France","author":"Million","year":"2020"},{"key":"10.1016\/j.therap.2020.05.010_bib0450","article-title":"Estimating the burden of SARS-CoV-2 in France","author":"Salje","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.therap.2020.05.010_bib0455","article-title":"Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data","volume":"369","author":"Mah\u00e9vas","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2020.05.010_bib0460","article-title":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19","author":"Magagnoli","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.therap.2020.05.010_bib0465","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","author":"Geleris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2020.05.010_bib0470","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2020.05.010_bib0475","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)","author":"Chen","year":"2020","journal-title":"J Zhejiang Univ"},{"key":"10.1016\/j.therap.2020.05.010_bib0480","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.therap.2020.05.010_bib0485","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2020.05.010_bib0490","series-title":"Meta evidence COVID-19","year":"2020"},{"key":"10.1016\/j.therap.2020.05.010_bib0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2020.05.001","article-title":"French network of regional pharmacovigilance centres. Adverse drug reactions of hydroxychloroquine: analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data","author":"Grandvuillemin","year":"2020","journal-title":"Therapies"},{"issue":"6","key":"10.1016\/j.therap.2020.05.010_bib0500","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1128\/AAC.05688-11","article-title":"In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials","volume":"56","author":"Borsini","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.therap.2020.05.010_bib0505","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/00002018-200124080-00002","article-title":"Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome","volume":"24","author":"Drici","year":"2001","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.therap.2020.05.010_bib0510","first-page":"185","article-title":"Cardiac K+ channels and drug-acquired long QT syndrome","volume":"55","author":"Drici","year":"2000","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2020.05.010_bib0515","series-title":"Hydroxychloroquine et azithromycine rappel sur le risque cardiaque","year":"2020"},{"issue":"10","key":"10.1016\/j.therap.2020.05.010_bib0520","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.hrthm.2015.05.027","article-title":"Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current if: novel electrophysiological insights and therapeutic potential","volume":"12","author":"Capel","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.therap.2020.05.010_bib0525","article-title":"No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial","author":"Mahevas","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.therap.2020.05.010_bib0530","article-title":"The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine\/azithromycin","author":"Chorin","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.therap.2020.05.010_bib0535","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.therap.2020.05.010_bib0540","author":"Borba","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.therap.2020.05.010_bib0545","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1787","article-title":"Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit","author":"Bessi\u00e8re","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.therap.2020.05.010_bib0550","article-title":"Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study","author":"Lane","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.therap.2020.05.010_bib0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2020.05.002","article-title":"\u201cOff-label\u201d use of hydroxychloroquine and else in COVID-19: complete survey of cardiac adverse reactions by the French Pharmacovigilance network","author":"Gerard","year":"2020","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2020.05.010_bib0560","article-title":"ACE2, IEC\/ARAII et infections \u00e0 COVID-19","year":"2020","journal-title":"Therapies"},{"issue":"12","key":"10.1016\/j.therap.2020.05.010_bib0565","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41584-018-0111-8","article-title":"Hydroxychloroquine retinopathy \u2014 implications of research advances for rheumatology care","volume":"14","author":"Jorge","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.therap.2020.05.010_bib0570","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/1744666X.2016.1212659","article-title":"Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus","volume":"13","author":"Mok","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.therap.2020.05.010_bib0575","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.therap.2020.05.010_bib0580","series-title":"Recommandations et publications","year":"2020"},{"key":"10.1016\/j.therap.2020.05.010_bib0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2020.04.016","article-title":"COVID-19 research has overall low methodological quality thus far: case in point for chloroquine\/hydroxychloroquine","author":"Alexander","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.therap.2020.05.010_bib0590","doi-asserted-by":"crossref","DOI":"10.1111\/fcp.12564","article-title":"Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic","author":"Larrouquere","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"issue":"7805","key":"10.1016\/j.therap.2020.05.010_bib0595","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/d41586-020-01165-3","article-title":"Chloroquine hype is derailing the search for coronavirus treatments","volume":"580","author":"Ledford","year":"2020","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.therap.2020.05.010_bib0600","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJM197905313002203","article-title":"A new design for randomized clinical trials","volume":"300","author":"Zelen","year":"1979","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.therap.2020.05.010_bib0605","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJM198405243102141","article-title":"Randomization designs in comparative clinical trials","volume":"310","author":"Ellenberg","year":"1984","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.therap.2020.05.010_bib0610","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:46Z","timestamp":1758567226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720301001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0040595720301001"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.010","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}